Bijay Nair

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

John Crowley, Pingping Qu, Bart Barlogie, 2011, Blood.

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2

David R Williams, Bart Barlogie, O. Stephens, 2010, Proceedings of the National Academy of Sciences.